An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer co... An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers. 詳細を表示
November 5, 2021 -- InvestorsHub NewsWire -- via Hawk Point Media -- Benzinga iQSTEL Inc.’s (OTCQX:IQST) market cap of $62M is absurdly low. In fact, 2021 revenues, if they...
CEO Presenting on the Emerging Growth Conference on October 13 Register Now Niche Companies in Technology, Biotech / Pharma, FinTech, Exploration, Wellness, and more in Attendance. Miami, Florida...
CEO's Presenting on the Emerging Growth Conference 17 TODAY. Register Now Niche Companies in Technology, Biotech / Pharma, FinTech, Exploration, Wellness, and more in...
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth Miami, FL--(September 28, 2021) – EmergingGrowth.com, a leading independent small cap media portal...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0001 | 0.0001 | 1.0E-6 | 121192 | 0.0001 | CS |
4 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 52468 | 0.0001 | CS |
12 | -0.0001 | -50 | 0.0002 | 0.0186 | 1.0E-6 | 259670 | 0.00014576 | CS |
26 | -0.001 | -90.9090909091 | 0.0011 | 0.0187 | 1.0E-6 | 286417 | 0.00032367 | CS |
52 | -0.0056 | -98.2456140351 | 0.0057 | 0.0195 | 1.0E-6 | 298082 | 0.00504173 | CS |
156 | -0.0439 | -99.7727272727 | 0.044 | 0.0649 | 1.0E-6 | 490059 | 0.02048602 | CS |
260 | -0.0899 | -99.8888888889 | 0.09 | 0.65 | 1.0E-6 | 1269229 | 0.17003568 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約